Glucagon-like peptide-1 receptor agonist (GLP-1) drugs, such as semaglutide, have become well known for their ability to aid ...

VENICE, Italy — Four-year data from the SELECT cardiovascular outcomes trial show that the anti-obesity drug semaglutide (Wegovy) leads to clinically significant and durable weight loss, as well as ...

Quality-of-life effects still a major unknown, researchers say ...

For years, semaglutide was framed as a powerful tool for diabetes and weight loss. Now cardiologists are confronting a more surprising reality: this same drug appears to protect the heart in ways that ...

Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and ...

Among patients who have obesity-related heart failure with preserved ejection fraction (HFpEF), once-weekly semaglutide 2.4 mg (Wegovy; Novo Nordisk) induces greater weight loss in women than in men ...

Semaglutide is at least as effective at preventing heart attacks and other cardiac events as well as death in people with impaired kidney function as it is in those with normal kidney function The ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE trial, ...

Studies link semaglutide to cardiovascular protection, fatty liver improvement, mental health gains and male fertility ...

Weight management medications are transforming the landscape of obesity treatment, with semaglutide emerging as a groundbreaking solution for individuals struggling with weight loss. As demand surges ...

Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity plus preexisting CVD had a reduction in CV event risk with semaglutide in ...

The anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don't ...